Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Industry Analysis and Forecast 2027: By Marker Type, End User and Region.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Industry Analysis and Forecast 2027: By Marker Type, End User and Region.

Market Scenario

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market was valued US$ XX Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a XX% CAGR of around XX% during a forecast period. Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Nonalcoholic steatohepatitis (NASH) is the active form of Nonalcoholic fatty liver disease (NAFLD), with hepatic necroinflammation and faster fibrosis progression. The unwanted fat deposition in liver is the key cause of this disease. If left untreated or undiagnosed, it can lead to liver cirrhosis and ultimately progress to liver failure. The high incidence of liver-related diseases has encourage some industry players and research institutes to spend in development of sophisticated NASH diagnostic and therapeutic products.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The scope of the report includes a detailed study of global and regional markets for Non-alcoholic Steatohepatitis (NASH) Biomarkers with the reasons given for variants in the growth of the industry in certain regions. The prevalence of NASH is rising at a shocking rate and thus has directed to the increasing need for effective diagnostic tools in recent years. The NASH Education Program reported that, the incidence of NASH is expected to increase by XX% during 2015 to 2027. The rising incidence of diabetes and obesity, increasing demand for non-invasive tests, and increasing public and private sector initiatives to upsurge awareness about NASH are anticipated to drive the growth of the market. Apart from this, the negative regulatory scenario is expected to affect market growth during forecast period. For example, the existence of stringent regulations by the US FDA for the limitation of biomarkers is expected to restrict the market growth. The report on Non-alcoholic Steatohepatitis (NASH) Biomarkers market covers segments such as Marker Type, End User and Region. The Marker Type segment includes Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others. Among the Marker Type, Serum Biomarkers is accounted for the largest XX% market share in the Non-alcoholic Steatohepatitis (NASH) Biomarkers market, due to their indirect relation with NASH. The Hepatic fibrosis markers are anticipated to raise exponentially during forecasted period due to their more accuracy and efficiency. This marker type segment is anticipated to hold the leading share of NASH biomarkers market by 2027. The End User segment is further sub-segmented into Pharmaceutical Companies and CROs, Research Institutes and Academics, Hospitals & Clinics, Diagnostic Centers, and Others. Because of the necessity of non-invasive diagnostic tools for routine observing of drug therapy efficiency in the course of clinical trial of drug candidates, the Pharmaceutical Companies and CROs end-user segment is anticipated to have a reasonable growth during the forecasted period. Based on regional segment, the Non-alcoholic Steatohepatitis (NASH) Biomarkers market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to hold leading position in the Non-alcoholic Steatohepatitis (NASH) Biomarkers market throughout the forecast period. Growth of this particular region is ascribed to the encouraging government initiatives, the presence of sophisticated healthcare amenities, and increasing incidence of diabetes, fatty liver disease, and obesity. Europe is expected to hold the second position in the non-alcoholic steatohepatitis (NASH) biomarkers market. The factors like growing prevalence of NASH, rising incidence of obesity and diabetics, existence of well-established healthcare sector, and growing research and development on liver diseases. The market growth in the Asia-Pacific region can be ascribed to factors like the existence of a large patient base, rise in healthcare spending, and availability of skilled healthcare personnel. The Middle East and Africa is expected to register the lowest share in the global market. In the African region, the market is expected to be negatively affected by factors like poor healthcare amenities, a smaller amount disposable income, inadequate awareness about liver diseases, including NASH. Key players operating in the Non-alcoholic Steatohepatitis (NASH) Biomarkers market are BioPredictive, Celerion, Cisbio, Echosens, Enterome, GENFIT, Laboratory Corporation of America Holdings, NGM Biopharmaceuticals, One Way Liver, SL, Pacific Biomarkers, Prometheus Laboratories Inc., Perspectrum Diagnostics Ltd, Quest Diagnostics, Regulus Therapeutics, Inc., Siemens Healthineers, Shenzhen New Industries Biomedical Engineering Co., Ltd, Xeptagen SpA, and Exalenz Biosciences Ltd. In November 2018, Siemens Healthineers declared that the US Food and Drug Administration (FDA) had approved an innovative device designation for its ELF test. In September 2018, Quest Diagnostics associated with Houston Healthcare to provide advanced laboratory services. With this, the company aims to brace its position in the market. Similar kind of strategies followed by the other players functioning in the non-alcoholic steatohepatitis biomarkers market were innovation, product development, acquisition, and expansion. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Non-alcoholic Steatohepatitis (NASH) Biomarkers market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Non-alcoholic Steatohepatitis (NASH) Biomarkers market.

Scope of the Non-alcoholic Steatohepatitis (NASH) Biomarkers Market

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By Marker Type

• Serum Biomarkers • Hepatic Fibrosis Biomarkers • Apoptosis Biomarkers • Oxidative Stress Biomarkers • Others

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By End User

• Pharmaceutical Companies and CROs • Research Institutes and Academics • Hospitals & Clinics • Diagnostic Centers • Others.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market

• BioPredictive, Celerion • Cisbio • Echosens • Enterome • GENFIT SA • Laboratory Corporation of America Holdings • NGM Biopharmaceuticals • One Way Liver SL • Pacific Biomarkers • Prometheus Laboratories Inc. • Perspectrum Diagnostics Ltd. • Quest Diagnostics • Regulus Therapeutics, Inc. • Siemens Healthineers • Shenzhen New Industries Biomedical Engineering Co., Ltd. • Xeptagen SpA • Exalenz Biosciences Ltd.

Table of Contents

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast 6.1. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast, By Marker Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By Marker Type 7.4. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Bn) Forecast, By Marker Type 7.5. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis, By Marker Type 7.6. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, By Marker Type 8. Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast, By End User 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By End User 8.4. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Bn) Forecast, By End User 8.5. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis, By End User 8.6. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, By End User 9. Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis, by Region 9.1. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Region 9.2. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Bn) Forecast, by Region 9.3. Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Region 10. North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis 10.1. Key Findings 10.2. North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Overview 10.3. North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By Marker Type 10.4. North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 10.4.1. Serum Biomarkers 10.4.2. Hepatic Fibrosis Biomarkers 10.4.3. Apoptosis Biomarkers 10.4.4. Oxidative Stress Biomarkers 10.4.5. Others 10.5. North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By End User 10.6. North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 10.6.1. Pharmaceutical Companies and CROs 10.6.2. Research Institutes and Academics 10.6.3. Hospitals & Clinics 10.6.4. Diagnostic Centers 10.6.5. Others. 10.7. North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country 10.8. North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis, by Country 10.10. U.S. Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 10.10.1. Serum Biomarkers 10.10.2. Hepatic Fibrosis Biomarkers 10.10.3. Apoptosis Biomarkers 10.10.4. Oxidative Stress Biomarkers 10.10.5. Others 10.11. U.S. Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 10.11.1. Pharmaceutical Companies and CROs 10.11.2. Research Institutes and Academics 10.11.3. Hospitals & Clinics 10.11.4. Diagnostic Centers 10.11.5. Others. 10.12. Canada Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 10.12.1. Serum Biomarkers 10.12.2. Hepatic Fibrosis Biomarkers 10.12.3. Apoptosis Biomarkers 10.12.4. Oxidative Stress Biomarkers 10.12.5. Others 10.13. Canada Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 10.13.1. Pharmaceutical Companies and CROs 10.13.2. Research Institutes and Academics 10.13.3. Hospitals & Clinics 10.13.4. Diagnostic Centers 10.13.5. Others. 10.14. North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis 10.14.1. By Marker Type 10.14.2. By End User 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Developments 11. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis 11.1. Key Findings 11.2. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Overview 11.3. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By Marker Type 11.4. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 11.4.1. Serum Biomarkers 11.4.2. Hepatic Fibrosis Biomarkers 11.4.3. Apoptosis Biomarkers 11.4.4. Oxidative Stress Biomarkers 11.4.5. Others 11.5. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By End User 11.6. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 11.6.1. Pharmaceutical Companies and CROs 11.6.2. Research Institutes and Academics 11.6.3. Hospitals & Clinics 11.6.4. Diagnostic Centers 11.6.5. Others. 11.7. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country 11.8. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis, by Country 11.10. Germany Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 11.10.1. Serum Biomarkers 11.10.2. Hepatic Fibrosis Biomarkers 11.10.3. Apoptosis Biomarkers 11.10.4. Oxidative Stress Biomarkers 11.10.5. Others 11.11. Germany Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 11.11.1. Pharmaceutical Companies and CROs 11.11.2. Research Institutes and Academics 11.11.3. Hospitals & Clinics 11.11.4. Diagnostic Centers 11.11.5. Others. 11.12. U.K. Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 11.12.1. Serum Biomarkers 11.12.2. Hepatic Fibrosis Biomarkers 11.12.3. Apoptosis Biomarkers 11.12.4. Oxidative Stress Biomarkers 11.12.5. Others 11.13. U.K. Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 11.13.1. Pharmaceutical Companies and CROs 11.13.2. Research Institutes and Academics 11.13.3. Hospitals & Clinics 11.13.4. Diagnostic Centers 11.13.5. Others. 11.14. France Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 11.14.1. Serum Biomarkers 11.14.2. Hepatic Fibrosis Biomarkers 11.14.3. Apoptosis Biomarkers 11.14.4. Oxidative Stress Biomarkers 11.14.5. Others 11.15. France Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 11.15.1. Pharmaceutical Companies and CROs 11.15.2. Research Institutes and Academics 11.15.3. Hospitals & Clinics 11.15.4. Diagnostic Centers 11.15.5. Others. 11.16. Italy Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 11.16.1. Serum Biomarkers 11.16.2. Hepatic Fibrosis Biomarkers 11.16.3. Apoptosis Biomarkers 11.16.4. Oxidative Stress Biomarkers 11.16.5. Others 11.17. Italy Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 11.17.1. Pharmaceutical Companies and CROs 11.17.2. Research Institutes and Academics 11.17.3. Hospitals & Clinics 11.17.4. Diagnostic Centers 11.17.5. Others. 11.18. Spain Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 11.18.1. Serum Biomarkers 11.18.2. Hepatic Fibrosis Biomarkers 11.18.3. Apoptosis Biomarkers 11.18.4. Oxidative Stress Biomarkers 11.18.5. Others 11.19. Spain Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 11.19.1. Pharmaceutical Companies and CROs 11.19.2. Research Institutes and Academics 11.19.3. Hospitals & Clinics 11.19.4. Diagnostic Centers 11.19.5. Others. 11.20. Rest of Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 11.20.1. Serum Biomarkers 11.20.2. Hepatic Fibrosis Biomarkers 11.20.3. Apoptosis Biomarkers 11.20.4. Oxidative Stress Biomarkers 11.20.5. Others 11.21. Rest of Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 11.21.1. Pharmaceutical Companies and CROs 11.21.2. Research Institutes and Academics 11.21.3. Hospitals & Clinics 11.21.4. Diagnostic Centers 11.21.5. Others. 11.22. Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis 11.22.1. By Marker Type 11.22.2. By End User 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Developments 12. Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis 12.1. Key Findings 12.2. Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Overview 12.3. Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By Marker Type 12.4. Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 12.4.1. Serum Biomarkers 12.4.2. Hepatic Fibrosis Biomarkers 12.4.3. Apoptosis Biomarkers 12.4.4. Oxidative Stress Biomarkers 12.4.5. Others 12.5. Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By End User 12.6. Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 12.6.1. Pharmaceutical Companies and CROs 12.6.2. Research Institutes and Academics 12.6.3. Hospitals & Clinics 12.6.4. Diagnostic Centers 12.6.5. Others. 12.7. Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country 12.8. Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis, by Country 12.10. China Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 12.10.1. Serum Biomarkers 12.10.2. Hepatic Fibrosis Biomarkers 12.10.3. Apoptosis Biomarkers 12.10.4. Oxidative Stress Biomarkers 12.10.5. Others 12.11. China Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 12.11.1. Pharmaceutical Companies and CROs 12.11.2. Research Institutes and Academics 12.11.3. Hospitals & Clinics 12.11.4. Diagnostic Centers 12.11.5. Others. 12.12. India Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 12.12.1. Serum Biomarkers 12.12.2. Hepatic Fibrosis Biomarkers 12.12.3. Apoptosis Biomarkers 12.12.4. Oxidative Stress Biomarkers 12.12.5. Others 12.13. India Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 12.13.1. Pharmaceutical Companies and CROs 12.13.2. Research Institutes and Academics 12.13.3. Hospitals & Clinics 12.13.4. Diagnostic Centers 12.13.5. Others. 12.14. Japan Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 12.14.1. Serum Biomarkers 12.14.2. Hepatic Fibrosis Biomarkers 12.14.3. Apoptosis Biomarkers 12.14.4. Oxidative Stress Biomarkers 12.14.5. Others 12.15. Japan Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 12.15.1. Pharmaceutical Companies and CROs 12.15.2. Research Institutes and Academics 12.15.3. Hospitals & Clinics 12.15.4. Diagnostic Centers 12.15.5. Others. 12.16. ASEAN Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 12.16.1. Serum Biomarkers 12.16.2. Hepatic Fibrosis Biomarkers 12.16.3. Apoptosis Biomarkers 12.16.4. Oxidative Stress Biomarkers 12.16.5. Others 12.17. ASEAN Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 12.17.1. Pharmaceutical Companies and CROs 12.17.2. Research Institutes and Academics 12.17.3. Hospitals & Clinics 12.17.4. Diagnostic Centers 12.17.5. Others. 12.18. Rest of Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 12.18.1. Serum Biomarkers 12.18.2. Hepatic Fibrosis Biomarkers 12.18.3. Apoptosis Biomarkers 12.18.4. Oxidative Stress Biomarkers 12.18.5. Others 12.19. Rest of Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 12.19.1. Pharmaceutical Companies and CROs 12.19.2. Research Institutes and Academics 12.19.3. Hospitals & Clinics 12.19.4. Diagnostic Centers 12.19.5. Others. 12.20. Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis 12.20.1. By Marker Type 12.20.2. By End User 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Developments 13. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Overview 13.3. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By Marker Type 13.4. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 13.4.1. Serum Biomarkers 13.4.2. Hepatic Fibrosis Biomarkers 13.4.3. Apoptosis Biomarkers 13.4.4. Oxidative Stress Biomarkers 13.4.5. Others 13.5. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By End User 13.6. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 13.6.1. Pharmaceutical Companies and CROs 13.6.2. Research Institutes and Academics 13.6.3. Hospitals & Clinics 13.6.4. Diagnostic Centers 13.6.5. Others. 13.7. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country 13.8. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis, by Country 13.10. GCC Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 13.10.1. Serum Biomarkers 13.10.2. Hepatic Fibrosis Biomarkers 13.10.3. Apoptosis Biomarkers 13.10.4. Oxidative Stress Biomarkers 13.10.5. Others 13.11. GCC Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 13.11.1. Pharmaceutical Companies and CROs 13.11.2. Research Institutes and Academics 13.11.3. Hospitals & Clinics 13.11.4. Diagnostic Centers 13.11.5. Others. 13.12. South Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 13.12.1. Pharmaceutical Companies and CROs 13.12.2. Research Institutes and Academics 13.12.3. Hospitals & Clinics 13.12.4. Diagnostic Centers 13.12.5. Others. 13.13. Rest of Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 13.13.1. Serum Biomarkers 13.13.2. Hepatic Fibrosis Biomarkers 13.13.3. Apoptosis Biomarkers 13.13.4. Oxidative Stress Biomarkers 13.13.5. Others 13.14. Rest of Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 13.14.1. Pharmaceutical Companies and CROs 13.14.2. Research Institutes and Academics 13.14.3. Hospitals & Clinics 13.14.4. Diagnostic Centers 13.14.5. Others. 13.15. Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis 13.15.1. By Marker Type 13.15.2. By End User 13.16. PEST Analysis 13.17. Key Trends 13.18. Key Developments 14. South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis 14.1. Key Findings 14.2. South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Overview 14.3. South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By Marker Type 14.4. South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 14.4.1. Serum Biomarkers 14.4.2. Hepatic Fibrosis Biomarkers 14.4.3. Apoptosis Biomarkers 14.4.4. Oxidative Stress Biomarkers 14.4.5. Others 14.5. South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, By End User 14.6. South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 14.6.1. Pharmaceutical Companies and CROs 14.6.2. Research Institutes and Academics 14.6.3. Hospitals & Clinics 14.6.4. Diagnostic Centers 14.6.5. Others. 14.7. South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country 14.8. South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis, by Country 14.10. Brazil Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 14.10.1. Serum Biomarkers 14.10.2. Hepatic Fibrosis Biomarkers 14.10.3. Apoptosis Biomarkers 14.10.4. Oxidative Stress Biomarkers 14.10.5. Others 14.11. Brazil Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 14.11.1. Pharmaceutical Companies and CROs 14.11.2. Research Institutes and Academics 14.11.3. Hospitals & Clinics 14.11.4. Diagnostic Centers 14.11.5. Others. 14.12. Mexico Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 14.12.1. Serum Biomarkers 14.12.2. Hepatic Fibrosis Biomarkers 14.12.3. Apoptosis Biomarkers 14.12.4. Oxidative Stress Biomarkers 14.12.5. Others 14.13. Mexico Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 14.13.1. Pharmaceutical Companies and CROs 14.13.2. Research Institutes and Academics 14.13.3. Hospitals & Clinics 14.13.4. Diagnostic Centers 14.13.5. Others. 14.14. Rest of South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By Marker Type 14.14.1. Serum Biomarkers 14.14.2. Hepatic Fibrosis Biomarkers 14.14.3. Apoptosis Biomarkers 14.14.4. Oxidative Stress Biomarkers 14.14.5. Others 14.15. Rest of South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Forecast, By End User 14.15.1. Pharmaceutical Companies and CROs 14.15.2. Research Institutes and Academics 14.15.3. Hospitals & Clinics 14.15.4. Diagnostic Centers 14.15.5. Others. 14.16. South America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis 14.16.1. By Marker Type 14.16.2. By End User 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Developments 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Route of Administrations and R&D investment 15.2.2. New Treatment Center Launches and Treatment Center Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Route of Administrations 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. BioPredictive, Celerion 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Treatment Center Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Cisbio 15.3.3. Echosens 15.3.4. Enterome 15.3.5. GENFIT SA 15.3.6. Laboratory Corporation of America Holdings 15.3.7. NGM Biopharmaceuticals 15.3.8. One Way Liver SL 15.3.9. Pacific Biomarkers 15.3.10. Prometheus Laboratories Inc. 15.3.11. Perspectrum Diagnostics Ltd. 15.3.12. Quest Diagnostics 15.3.13. Regulus Therapeutics, Inc. 15.3.14. Siemens Healthineers 15.3.15. Shenzhen New Industries Biomedical Engineering Co., Ltd. 15.3.16. Xeptagen SpA 15.3.17. Exalenz Biosciences Ltd. 16. Primary Key Insights

About This Report

Report ID37239
Category Healthcare
Published DateNov 2019
No of Pages190
Contact Us
Call Now